Test data show potency of drug candidate for hepatitis C

Idenix Pharmaceuticals reported interim data from a Phase IIb trial showing that its lead hepatitis C agent reduced viral load to an undetectable level after 28 days in 73% of patients given a 100-milligram dose and 63% of those who took 50 milligrams. "In 2012, we will build on this progress and believe we are well positioned to play a major role in treating [hepatitis C virus] patients for the foreseeable future," said CEO Ron Renaud. Idenix also began an early-stage study of nucleotide inhibitor IDX719 and chose two similar compounds as potential drug candidates. The Wall Street Journal

Source: AABBsmartbrief